Frontlight ResearchEarly access
WithdrawnPhase 2
Ketamine for the Treatment for Alcohol Use Disorder in the ED
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Sept 2023
- Ended
- 19 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketamine
- Saline
- Record updated
- 8 January 2025
- Why it stopped
- After months of screening, we screened 175 individuals, only 3 were eligible, 2 declined, and 1 was moved to a different floor before study activities were able to take place.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- English speaking adults aged 18 and above
- Diagnosed with DSM5 alcohol use disorder, severe
- Admitted to BWF inpatient withdrawal management unit (Addiction Recovery Program)
Who cannot take part
- Alcohol withdrawal seizure prior to or during the ED visit
- Current use of medications with known drug-drug interactions with ketamine (i.e., St. John's Wort, theophylline, opioid analgesics, CNS depressants other than benzodiazepines or phenobarbital)
- Any psychotic disorder, bipolar disorder, active suicidality or homicidality
- Systolic blood pressure persistently elevated above 180mmHg, or heart rate >130bmp, in the ED
- History of hypersensitivity to ketamine, or experience of emergence reaction
- History of any illicit or recreational use of ketamine
- History of DSM5 hallucinogen use disorder, intracranial mass or bleed, porphyria, thyrotoxicosis, seizure disorder other than from alcohol withdrawal, liver cirrhosis, renal failure, obstructive lung disease, or sleep apnea
- History within 6 months of head trauma, stroke, or myocardial infarction
- Inability to perform consent due to impaired mental status
- Clinical Institute Withdrawal Assessment (CIWA) score > 20 at any point in the ED
- Receipt of ketamine treatment for depression in the past 3 months
- Liver dysfunction with LFTs >3x upper normal limit
- Pregnant
Where in United States
- Brigham and Women's Faulkner HospitalBoston, United States
About the trial
What the trial wants to find out
The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo. The primary aim is to evaluate the intervention's safety. The secondary aim is to evaluate the preliminary efficacy of alcohol-related outcomes.
The 2 groups in the trial
- KetamineTreatment being tested
This arm will receive ketamine (n=25)
- PlaceboPlacebo, for comparison
This arm will receive the saline placebo (n=25)
Treatment: Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ketamine for the Treatment for Alcohol Use Disorder in the Emergency Department: A Pilot Double-blind, Placebo-controlled Randomized Clinical Trial
- Record updated
- 8 January 2025